Serum thymidine activity and somatomedin-c levels in children and adolescents with turner’s syndrome: Effect of chronic estrogen and progestogen replacement therapy

Sylvie Guidoux, Mauro Bozzola, Daniela Larizza, Rose Marie Schimpff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Turner’s syndrome has been used as a model of primary hypogonadism to assess the role of estrogen-progestogen replacement therapy on scrum thymidine activity (TA) and somatomcdin-C (Sm-C) levels. 33 subjects with gonadal dysgenesis were studied: 10 untreated and 13 treated with estrogen-progestogen combination. In 10 untreated patients serum TA was 1.02 ± (SEM) 0.04 U/ml and serum Sm-C value was 27.82 ±4.14 nmol/1. both similar to those in the age-matched normal children. A positive correlation was found between Sm-C and the bone age (r = 0.891. ρ <0.002). In the i3 treated subjects, the estrogen-progestogen combination as replacement therapy induced a significant increase in Sm-C level (40.52 ± 4.30 nmol/1, ρ <0.05). No variation was observed for serum thymidine activity between the two groups of subjects.

Original languageEnglish
Pages (from-to)256-262
Number of pages7
JournalHormone Research in Paediatrics
Volume24
Issue number4
DOIs
Publication statusPublished - 1986

Fingerprint

Turner Syndrome
Estrogen Replacement Therapy
Somatomedins
Progestins
Thymidine
Estrogens
Serum
Gonadal Dysgenesis
Hypogonadism
Bone and Bones
Therapeutics

Keywords

  • Estrogen replacement therapy
  • Sm-C
  • Thymidine activity
  • Tumor’s syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{7c65448aae694a46956d9a66a17358d0,
title = "Serum thymidine activity and somatomedin-c levels in children and adolescents with turner’s syndrome: Effect of chronic estrogen and progestogen replacement therapy",
abstract = "Turner’s syndrome has been used as a model of primary hypogonadism to assess the role of estrogen-progestogen replacement therapy on scrum thymidine activity (TA) and somatomcdin-C (Sm-C) levels. 33 subjects with gonadal dysgenesis were studied: 10 untreated and 13 treated with estrogen-progestogen combination. In 10 untreated patients serum TA was 1.02 ± (SEM) 0.04 U/ml and serum Sm-C value was 27.82 ±4.14 nmol/1. both similar to those in the age-matched normal children. A positive correlation was found between Sm-C and the bone age (r = 0.891. ρ <0.002). In the i3 treated subjects, the estrogen-progestogen combination as replacement therapy induced a significant increase in Sm-C level (40.52 ± 4.30 nmol/1, ρ <0.05). No variation was observed for serum thymidine activity between the two groups of subjects.",
keywords = "Estrogen replacement therapy, Sm-C, Thymidine activity, Tumor’s syndrome",
author = "Sylvie Guidoux and Mauro Bozzola and Daniela Larizza and Schimpff, {Rose Marie}",
year = "1986",
doi = "10.1159/000180565",
language = "English",
volume = "24",
pages = "256--262",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Serum thymidine activity and somatomedin-c levels in children and adolescents with turner’s syndrome

T2 - Effect of chronic estrogen and progestogen replacement therapy

AU - Guidoux, Sylvie

AU - Bozzola, Mauro

AU - Larizza, Daniela

AU - Schimpff, Rose Marie

PY - 1986

Y1 - 1986

N2 - Turner’s syndrome has been used as a model of primary hypogonadism to assess the role of estrogen-progestogen replacement therapy on scrum thymidine activity (TA) and somatomcdin-C (Sm-C) levels. 33 subjects with gonadal dysgenesis were studied: 10 untreated and 13 treated with estrogen-progestogen combination. In 10 untreated patients serum TA was 1.02 ± (SEM) 0.04 U/ml and serum Sm-C value was 27.82 ±4.14 nmol/1. both similar to those in the age-matched normal children. A positive correlation was found between Sm-C and the bone age (r = 0.891. ρ <0.002). In the i3 treated subjects, the estrogen-progestogen combination as replacement therapy induced a significant increase in Sm-C level (40.52 ± 4.30 nmol/1, ρ <0.05). No variation was observed for serum thymidine activity between the two groups of subjects.

AB - Turner’s syndrome has been used as a model of primary hypogonadism to assess the role of estrogen-progestogen replacement therapy on scrum thymidine activity (TA) and somatomcdin-C (Sm-C) levels. 33 subjects with gonadal dysgenesis were studied: 10 untreated and 13 treated with estrogen-progestogen combination. In 10 untreated patients serum TA was 1.02 ± (SEM) 0.04 U/ml and serum Sm-C value was 27.82 ±4.14 nmol/1. both similar to those in the age-matched normal children. A positive correlation was found between Sm-C and the bone age (r = 0.891. ρ <0.002). In the i3 treated subjects, the estrogen-progestogen combination as replacement therapy induced a significant increase in Sm-C level (40.52 ± 4.30 nmol/1, ρ <0.05). No variation was observed for serum thymidine activity between the two groups of subjects.

KW - Estrogen replacement therapy

KW - Sm-C

KW - Thymidine activity

KW - Tumor’s syndrome

UR - http://www.scopus.com/inward/record.url?scp=0022469013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022469013&partnerID=8YFLogxK

U2 - 10.1159/000180565

DO - 10.1159/000180565

M3 - Article

C2 - 3781484

AN - SCOPUS:0022469013

VL - 24

SP - 256

EP - 262

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 4

ER -